Cellectis, the French biotech company, is in talks about its potential sale with Pfizer of the US believed to be among the buyers.
Two people familiar with the situation said Cellectis was in negotiations over a deal but warned that no outcome was certain. One person said Pfizer had informally approached the company about a deal that could value the target at as much as €1.5bn.
The US drug company already owns 9.47 per cent of Cellectis after the pair forged a partnership to develop cancer drugs.
您已阅读15%（499字），剩余85%（2827字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。